US 12,486,331 B2
Bispecific T cell engagers
Margaret Karow, Newbury Park, CA (US); Richard Yau, Newbury Park, CA (US); and Jackie Sheng, Newbury Park, CA (US)
Assigned to Gensun Biopharma Inc., Newbury Park, CA (US)
Filed by Gensun Biopharma (MXY), Newbury Park, CA (US)
Filed on Mar. 21, 2024, as Appl. No. 18/612,342.
Application 18/612,342 is a continuation of application No. 17/164,699, filed on Feb. 1, 2021, granted, now 11,976,133.
Claims priority of provisional application 62/991,070, filed on Mar. 17, 2020.
Claims priority of provisional application 62/981,048, filed on Feb. 25, 2020.
Claims priority of provisional application 62/968,999, filed on Jan. 31, 2020.
Prior Publication US 2024/0343827 A1, Oct. 17, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/3092 (2013.01) [A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/28 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/2878 (2013.01); C07K 16/30 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/74 (2013.01); C07K 2317/75 (2013.01); C07K 2319/33 (2013.01)] 18 Claims
 
1. A monoclonal antibody that binds to human Delta-like ligand 3 (DLL3), comprising an antigen binding fragment comprising a combination of CDRs selected from the group consisting of:
(1) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:16, an HCDR3 sequence of SEQ ID NO:24, an LCDR1 sequence of SEQ ID NO:33, an LCDR2 sequence of SEQ ID NO:43, and an LCDR3 sequence of SEQ ID NO:49,
(2) an HCDR1 sequence of SEQ ID NO:7, an HCDR2 sequence of SEQ ID NO:14, an HCDR3 sequence of SEQ ID NO:27, an LCDR1 sequence of SEQ ID NO:31, an LCDR2 sequence of SEQ ID NO:40, and an LCDR3 sequence of SEQ ID NO:47,
(3) an HCDR1 sequence of SEQ ID NO:1, an HCDR2 sequence of SEQ ID NO:11, an HCDR3 sequence of SEQ ID NO:22, an LCDR1 sequence of SEQ ID NO:32, an LCDR2 sequence of SEQ ID NO:39, and an LCDR3 sequence of SEQ ID NO:54,
(4) an HCDR1 sequence of SEQ ID NO:5, an HCDR2 sequence of SEQ ID NO:16, an HCDR3 sequence of SEQ ID NO:24, an LCDR1 sequence of SEQ ID NO:33, an LCDR2 sequence of SEQ ID NO:43, and an LCDR3 sequence of SEQ ID NO:49,
(5) an HCDR1 sequence of SEQ ID NO:2, an HCDR2 sequence of SEQ ID NO:10, an HCDR3 sequence of SEQ ID NO:22, an LCDR1 sequence of SEQ ID NO:32, an LCDR2 sequence of SEQ ID NO:46, and an LCDR3 sequence of SEQ ID NO:55,
(6) an HCDR1 sequence of SEQ ID NO:1, an HCDR2 sequence of SEQ ID NO:11, an HCDR3 sequence of SEQ ID NO:22, an LCDR1 sequence of SEQ ID NO:32, an LCDR2 sequence of SEQ ID NO:46, and an LCDR3 sequence of SEQ ID NO:55,
(7) an HCDR1 sequence of SEQ ID NO:4, an HCDR2 sequence of SEQ ID NO:12, an HCDR3 sequence of SEQ ID NO:23, an LCDR1 sequence of SEQ ID NO:36, an LCDR2 sequence of SEQ ID NO:44, and an LCDR3 sequence of SEQ ID NO:48,
(8) an HCDR1 sequence of SEQ ID NO:3, an HCDR2 sequence of SEQ ID NO:13, an HCDR3 sequence of SEQ ID NO:28, an LCDR1 sequence of SEQ ID NO:32, an LCDR2 sequence of SEQ ID NO:46, and an LCDR3 sequence of SEQ ID NO:54,
(9) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:15, an HCDR3 sequence of SEQ ID NO:25, an LCDR1 sequence of SEQ ID NO:33, an LCDR2 sequence of SEQ ID NO:43, and an LCDR3 sequence of SEQ ID NO:51,
(10) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:16, an HCDR3 sequence of SEQ ID NO:25, an LCDR1 sequence of SEQ ID NO:33, an LCDR2 sequence of SEQ ID NO:43, and an LCDR3 sequence of SEQ ID NO:51,
(11) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:18, an HCDR3 sequence of SEQ ID NO:25, an LCDR1 sequence of SEQ ID NO:33, an LCDR2 sequence of SEQ ID NO:43, and an LCDR3 sequence of SEQ ID NO:51,
(12) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:15, an HCDR3 sequence of SEQ ID NO:24, an LCDR1 sequence of SEQ ID NO:34, an LCDR2 sequence of SEQ ID NO:43, and an LCDR3 sequence of SEQ ID NO:49,
(13) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:16, an HCDR3 sequence of SEQ ID NO:24, an LCDR1 sequence of SEQ ID NO:34, an LCDR2 sequence of SEQ ID NO:43, and an LCDR3 sequence of SEQ ID NO:49,
(14) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:18, an HCDR3 sequence of SEQ ID NO:24, an LCDR1 sequence of SEQ ID NO:34, an LCDR2 sequence of SEQ ID NO:43, and an LCDR3 sequence of SEQ ID NO:49,
(15) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:15, an HCDR3 sequence of SEQ ID NO:25, an LCDR1 sequence of SEQ ID NO:37, an LCDR2 sequence of SEQ ID NO:42, and an LCDR3 sequence of SEQ ID NO:51,
(16) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:16, an HCDR3 sequence of SEQ ID NO:25, an LCDR1 sequence of SEQ ID NO:37, an LCDR2 sequence of SEQ ID NO:42, and an LCDR3 sequence of SEQ ID NO:51,
(17) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:18, an HCDR3 sequence of SEQ ID NO:25, an LCDR1 sequence of SEQ ID NO:37, an LCDR2 sequence of SEQ ID NO:42, and an LCDR3 sequence of SEQ ID NO:51,
(18) an HCDR1 sequence of SEQ ID NO:7, an HCDR2 sequence of SEQ ID NO:15, an HCDR3 sequence of SEQ ID NO:24, an LCDR1 sequence of SEQ ID NO:38, an LCDR2 sequence of SEQ ID NO:42, and an LCDR3 sequence of SEQ ID NO:49,
(19) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:16, an HCDR3 sequence of SEQ ID NO:24, an LCDR1 sequence of SEQ ID NO:38, an LCDR2 sequence of SEQ ID NO:42, and an LCDR3 sequence of SEQ ID NO:49,
(20) an HCDR1 sequence of SEQ ID NO:6, an HCDR2 sequence of SEQ ID NO:18, an HCDR3 sequence of SEQ ID NO:24, an LCDR1 sequence of SEQ ID NO:38, an LCDR2 sequence of SEQ ID NO:42, and an LCDR3 sequence of SEQ ID NO:49,
(21) an HCDR1 sequence of SEQ ID NO:5, an HCDR2 sequence of SEQ ID NO:16, an HCDR3 sequence of SEQ ID NO:25, an LCDR1 sequence of SEQ ID NO:33, an LCDR2 sequence of SEQ ID NO:43, and an LCDR3 sequence of SEQ ID NO:51,
(22) an HCDR1 sequence of SEQ ID NO:5, an HCDR2 sequence of SEQ ID NO:16, an HCDR3 sequence of SEQ ID NO:24, an LCDR1 sequence of SEQ ID NO:34, an LCDR2 sequence of SEQ ID NO:43, and an LCDR3 sequence of SEQ ID NO:49,
(23) an HCDR1 sequence of SEQ ID NO:8, an HCDR2 sequence of SEQ ID NO:19, an HCDR3 sequence of SEQ ID NO:23, an LCDR1 sequence of SEQ ID NO:35, an LCDR2 sequence of SEQ ID NO:45, and an LCDR3 sequence of SEQ ID NO:52, and
(24) an HCDR1 sequence of SEQ ID NO:9, an HCDR2 sequence of SEQ ID NO:21, an HCDR3 sequence of SEQ ID NO:29, an LCDR1 sequence of SEQ ID NO:32, an LCDR2 sequence of SEQ ID NO:39, and an LCDR3 sequence of SEQ ID NO:54,
wherein the monoclonal antibody binds to human DLL3.